TRESP Recruitment - Medtech and Healthtech Experts’ Post

When Foes Become Friends: Abbott Teams Up With Medtronic – MedCity News - MedCity News #Collaboration: Abbott and Medtronic Join Forces in Diabetes Management In a surprising turn of events, two major players in the healthcare industry, Abbott and Medtronic, have decided to collaborate in the field of diabetes management. This partnership aims to revolutionize the way diabetes is treated and monitored, bringing together the expertise and resources of both companies. #Background: Abbott and Medtronic's Individual Contributions to Diabetes Care Abbott is known for its innovative glucose monitoring systems, while Medtronic is a leader in insulin delivery devices. By combining their strengths, they hope to create a more comprehensive and integrated solution for diabetes patients. #Benefits: Improved Patient Outcomes and User Experience The collaboration between Abbott and Medtronic is expected ai.mediformatica.com #abbott #insulin #medtronic #automatedinsulindelivery #delivery #glucose #technology #this #glucosemonitoring #levels #medical #monitoring #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/4cpwxb7)

Bigfoot Biomedical & Abbott 9 months ago Abbot acquired Bigfoot Biomedical, a company specialising in smart insulin management systems. Abbot acquired this technology to combine it with their own technology in insulin management - the FreeStyle Libre portfolio strengthening their ability to develop connected solutions for Diabetes. This article looks at the acquisition 9 months later and how they see the market moving forward. Yes there is risk with the rise of GLP-1 and other competitors such as Medtronic, but the future still looks bright. I personally believe this technology could be the best way manage diabetes. Yes the drug/medicine is important, but the data to know how much insulin to administer and when, to reach peak levels of health, may be the answer to diabetes patients living long and happy lives! Check out the article! #drugdelivery #medicaldevice #diabetes

Abbott continues to solidify its leadership in the medical devices and diabetes management sectors, with strong third-quarter earnings. The growth was driven by cutting-edge innovations, particularly in continuous glucose monitoring (CGM) and cardiovascular devices.    Abbott's FreeStyle Libre remains a frontrunner in diabetes care, empowering millions to manage their condition more effectively. The company's investment in technology is shaping the future of healthcare, bringing life-changing solutions to patients globally. 🚀💼    𝐕𝐢𝐬𝐢𝐭 𝐭𝐡𝐞 𝐋𝐈𝐍𝐊 𝐭𝐨 𝐞𝐱𝐩𝐥𝐨𝐫𝐞 𝐦𝐨𝐫𝐞: https://lnkd.in/gQPAn_Tr   #Navro #MyNavro #HealthcareIndustry #MedicalIndustry #HealthcareRecruitment #HealthcareInnovation #MedicalDevices #DiabetesCare #CGM #TechInHealthcare #Abbott #HealthcareLeadership #MedTech #CardiovascularHealth #GlobalHealth #FreeStyleLibre #DiabetesManagement #DigitalHealth #WearableTech #MedDeviceInnovation #HealthTech

The biggest stories from the 2024 J.P. Morgan Healthcare Conference The 2024 J.P. Morgan #Healthcare Conference highlighted key developments in the #medtech industry. 1. Medtronic focused on restoring earnings power and operational efficiency, announcing a new #AI Center of Excellence. 2. Abbott celebrated the success of its #FreeStyle Libre system, a revolutionary continuous glucose monitor. 3. Shockwave Medical shared its growth strategies, emphasizing product launches and global expansion. 4. Dexcom unveiled #Stelo, a new sensor for non-insulin-dependent type 2 diabetes patients. 5. Johnson & Johnson MedTech discussed growth through mergers and acquisitions, and #Insulet showcased the success of its #Omnipod 5 system in the automated insulin delivery market. For a detailed read, please visit the original article on MassDevice: Sean Whooley #medtech #surgicalinnovation #jpm2024 https://lnkd.in/gBK_vkAc

Just came across this article on MedTech Dive, highlighting the competition between Insulet, Tandem, and Medtronic in the patch pump space. It's fascinating to witness the innovations and advancements in diabetes management, and how companies are pushing the boundaries to enhance patient experience. The race for superior technology is not just a competition between companies; it's a commitment to improving lives. Kudos to Insulet, Tandem, and Medtronic for their hard work -- many good things to come. #diabetes #meddevice #insulet #tandem #medtronic https://lnkd.in/eQYSWZJb

🔍 Medtronic & Abbott Join Forces to Revolutionise Diabetes Tech! 🤝 In a game-changing move, Medtronic and Abbott have announced a collaboration that could reshape the diabetes tech landscape. Abbott will design a continuous glucose monitoring (CGM) system based on its FreeStyle Libre technology, which will be integrated with Medtronic's automated insulin delivery (AID) and smart insulin pen systems. 🩸💉 This partnership aims to enhance glucose control by automating insulin adjustments, making diabetes management easier and more efficient. Medtronic will exclusively sell the CGM designed by Abbott, further simplifying the lives of people with diabetes. What This Means for the Industry: -Impact on Competitors: While this collaboration strengthens Medtronic and Abbott’s position, companies like Dexcom and Insulet might feel the ripple effects. Dexcom could face challenges in converting Medtronic users, while Insulet’s patch pump market seems less threatened. -Expanding Access: Medtronic aims to broaden access to its AID and smart MDI systems, providing more people with advanced diabetes management tools. -Future Innovations: Medtronic is also advancing its own CGM technology, with the FDA-approved Simplera CGM, a disposable sensor that is half the size of its predecessors. 🚀 This partnership underscores the ongoing innovation in diabetes care, with the goal of making life easier for those managing this condition. 🌟 #DiabetesTech #MedTech #Innovation #Healthcare #Medtronic #Abbott #CGM #InsulinDelivery #HealthcareInnovation #DigitalHealth #MedicalDevices #DiabetesCare

Glucotrack is advancing diabetes care by teaming up with Cirtec Medical to bring an implantable Continuous Blood Glucose Monitor to life. Dive into how this collaboration could change the game for diabetes management. Read the full article by clicking below. #HealthTech #Innovation

The global market for Disposable Patient Controlled Analgesia PumpPCA Pump was estimated to be worth US$ 490.2 million in 2023 and is forecast to a readjusted size of US$ 711.8 million by 2030 with a CAGR of 5.6% during the forecast period 20242030The global medical device market is estimated to be US$603.3 billion in 2023 and is expected to grow at a CAGR of 5% over the next six years. #PCAPump #PainManagement #HealthcareInnovation #MedicalDevices #PatientCare #GlobalMarket #ChronicPain #PostOperativeCare #HealthcareTechnology #PatientSatisfaction

The global market for Blood Processing Consumables was estimated to be worth US$ 18430 million in 2023 and is forecast to a readjusted size of US$ 29800 million by 2030 with a CAGR of 6.3% during the forecast period 20242030According to our research the global market for medical devices is estimated at US$ 603 billion in the year 2023 and will be growing at a CAGR of 5% during next six years. #BloodProcessing #Healthcare #MedicalDevices #BloodBanks #Hospitals #BloodSafety #GlobalMarket #BloodConsumables #PatientCare #MedicalInnovation

Read an interesting case study from Abbott, a company founded in 1888 and now in its 136th year of operation, supplying healtcare products to 162 countries with an annual revenue of $40.1Bn. Abbott is committed to innovation and has a remarkable history of breakthrough inventions, including antiseptics for wounded soldiers in WW I, vitamins, intravenous solutions, Similac baby foods, and groundbreaking diagnostics like the first licensed HIV blood test. The case study, narrated by Abbott's CEO, Mr. Robert B Ford, highlights the journey of innovation with the launch of Freestyle Navigator in 2008 to improve the lives of people with diabetes. Before its launch they had to prick 10 times a day with painful finger-stick blood draws. Navigator instead offerred continuos monitoring of real-time glucose data via a sensor attached to the arm. Within a year need was felt to design a delivery device that was simpler , more user-friendly, and affordable. It's difficult to scrap a product that you spent years developing and that many customers have come to rely on. But that's what Abbott did. The initial bulky and expensive design led Abbott to pivot and introduce the more user-friendly Freestyle Libre in 2014, generating $5Bn in revenue last year and becoming the most successful medical device. I'm sharing the lessons learnt from this case as it will be useful to every business - 1) anticipate disruption of your products and markets created, and opt to disrupt yourselves before competitors could. 2) Focus on customers and listen deeply to their feedbacks and concerns 3) find out ways to eliminate complexity without sacrificing technical excellence 4) insist on putting out a product that would have a broadly positive impact ( in this case on as many people with diabetes as possible) not just on your bottomline. 5) communicate shift to key opinion leaders in the industry and to customers 6) it'simportant to manage ongoing operations and transformation in tandem and celebrate both sides equally. Maintain culture of collaboration while continuing to drive innovation. 7) There is always something to improve - or change 8) successful CGM pivot wouldn't have happened without a shift to more open, cross-functional teamwork and more consumer-led innovation. 9) If you have a big problem that needs to be addressed but your first solution is so-so, resist the urge to stick with what you've got. Try again from different angle. 10) though Abbott created financially successful products, higher level of reward is that people all over world tell Abbott that they have changed their lives. For deeper insights kindly find below the link to the article published in Harvard Business Review September-October 2024